{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T02:35:55Z","timestamp":1785551755378,"version":"3.56.0"},"reference-count":151,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T00:00:00Z","timestamp":1752019200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T00:00:00Z","timestamp":1752019200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medizinische Hochschule Hannover (MHH)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Dihydralazine and hydralazine have been on the market since the 1950s. The primary indication for those is the treatment of hypertension. The aim of this study is to uncover the reasons why both, dihydralazine in Germany and hydralazine in the USA, have lost importance. The period under investigation covers the years 1955 to 2025. The standard work from the USA\n                    <jats:italic>The Pharmacological Basis of Therapeutics<\/jats:italic>\n                    (Goodman &amp; Gilman) and three German pharmacology textbooks were selected:\n                    <jats:italic>Allgemeine und spezielle Pharmakologie und Toxikologie<\/jats:italic>\n                    (Aktories),\n                    <jats:italic>Pharmakologie und Toxikologie<\/jats:italic>\n                    (L\u00fcllmann) and\n                    <jats:italic>Allgemeine und Spezielle Pharmakologie und Toxikologie<\/jats:italic>\n                    (Karow). Categories were created for the German and US textbooks. Clinical studies were used to evaluate the textbooks. In addition, the \u201cRote Liste\u201d (Red List) of drugs was examined for each decade to identify changes. Guidelines and specialist information were also analyzed. Furthermore, learning platforms were examined about the learning content on dihydralazine. The textbooks show that dihydralazine is now only a reserve drug. Hydralazine is also no longer the drug of choice in the USA. The reason for the change in the evaluation of (di)hydralazines is the large number of adverse drug reactions (ADRs). In Goodman &amp; Gilman, the areas of application increased from 1955 to 2023, whereas German pharmacology textbooks (Aktories) and (L\u00fcllmann) show a decrease in indications over time. The (di)hydralazines now have an indication for chronic heart failure (CHF) in African Americans. The dose of hydralazine in the US and dihydralazine in Germany has been reduced over time. The (di)hydralazines have a wide spectrum of ADRs. Dihydralazine is no longer on the German drug list for medical exams. However, it is still covered on learning platforms. Dihydralazine in Germany and hydralazine in the USA have lost pharmacological importance but they are still used in individual situations, if tolerated, to reduce blood presssure.\n                  <\/jats:p>","DOI":"10.1007\/s00210-025-04370-x","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T09:35:49Z","timestamp":1752140149000},"page":"459-478","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The change in the pharmacological significance of dihydralazine (Germany) and hydralazine (USA)"],"prefix":"10.1007","volume":"399","author":[{"given":"Carina","family":"Mech","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Seifert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,9]]},"reference":[{"key":"4370_CR1","unstructured":"Aktories K, F\u00f6rstermann U, Hoffmann F, Starke K (2005) Allgemeine und spezielle Pharmakologie und Toxikologie, 9th edn. Elsevier Urban & Fischer Aktories, founded by: Forth, Wolfgang; Henschler, Dietrich; Rummel, Walter"},{"key":"4370_CR2","unstructured":"Aktories K, F\u00f6rstermann U, Hoffmann F, Starke K (2009) Allgemeine und spezielle Pharmakologie und Toxikologie, 10th edn. Elsevier Urban & Fischer Aktories, founded by: Forth, Wolfgang; Henschler, Dietrich; Rummel, Walter"},{"key":"4370_CR3","unstructured":"Aktories K, F\u00f6rstermann U, Hoffmann F, Starke K (2013) Allgemeine und spezielle Pharmakologie und Toxikologie, 11th edn. Elsevier Urban & Fischer Aktories, founded by: Forth, Wolfgang; Henschler, Dietrich; Rummel, Walter"},{"key":"4370_CR4","unstructured":"Aktories K, F\u00f6rstermann U, Hoffmann F, Starke K (2017) Allgemeine und spezielle Pharmakologie und Toxikologie, 12th edn. Elsevier Urban & Fischer Aktories, founded by: Forth, Wolfgang; Henschler, Dietrich; Rummel, Walter"},{"key":"4370_CR5","unstructured":"Aktories K, Flockerzi V, F\u00f6rstermann U, Hoffmann F (2022) Allgemeine und spezielle Pharmakologie und Toxikologie, 13th edn. Elsevier Urban & Fischer Aktories, founded by: Forth, Wolfgang; Henschler, Dietrich; Rummel, Walter"},{"key":"4370_CR6","unstructured":"Amboss. https:\/\/www.amboss.com\/de. Accessed 8.03.2025"},{"key":"4370_CR7","unstructured":"BiDil. https:\/\/bidil.com\/. Accessed 07.05.2025"},{"key":"4370_CR8","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/S0301-2115(00)00368-7","volume":"95","author":"AC Bolte","year":"2001","unstructured":"Bolte AC, Geijn HP, Dekker GA (2001) Pharmacological treatment of severe hypertension in pregnancy and the role of serotoinin 2-receptor blockers. Eur J Obstet Gynecol Reprod Biol 95:22\u201336. https:\/\/doi.org\/10.1016\/S0301-2115(00)00368-7","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"4370_CR9","doi-asserted-by":"crossref","unstructured":"Bopp A, Herren T, Matter H, Wyder D, Rudiger A (2021) Die Hypertensive Krise 21:702\u20137011","DOI":"10.4414\/smf.2021.08799"},{"key":"4370_CR10","unstructured":"Brody H, Hunt LM (2006) Reflection. BiDil: Assessing a race-based pharmaceutical.\u00a0https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC1687161\/pdf\/0040556.pdf"},{"key":"4370_CR11","unstructured":"Brunton L L, Lazo J S, Parker K L (2006) The pharmacological basis of therapeutics, 11th edn. McGraw-Hill"},{"key":"4370_CR12","unstructured":"Brunton L, Chabner B, Knollmann B (2011) The pharmacological basis of therapeutics, 12th edn. McGraw-Hill"},{"key":"4370_CR13","unstructured":"Brunton LL, Dandan R-H, Knollmann BC (2018) The pharmacological basis of therapeutics, 13th edn. McGraw-Hill"},{"key":"4370_CR14","unstructured":"Brunton LL, Knollmann BC (2023) The pharmacological basis of therapeutics, 14th edn. McGraw-Hill"},{"key":"4370_CR15","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1136\/bmj.289.6442.410","volume":"289","author":"HA Cameron","year":"1984","unstructured":"Cameron HA, Ramsay LE (1984) The lupus syndrome induced by hydralazine: a common complication with low dose treatment. BMJ 289:410\u2013412","journal-title":"BMJ"},{"key":"4370_CR16","unstructured":"Cardio Card Chronische Herzinsuffizienz (2023) https:\/\/leitlinien.dgk.org\/files\/09_2024_cardiocard_herzinsuffizienz_focused_update_2023"},{"key":"4370_CR17","unstructured":"CDC\u00b4s division for heart disease and stroke prevention: advancing heart health during american heart month beyond (2024) https:\/\/www.nhlbi.nih.gov\/healthy-hearts-network-partner-spotlight\/cdcs-division-heart-disease-and-stroke-prevention. Accessed 07.05.2025"},{"key":"4370_CR18","unstructured":"CDC Heart Disease (2024) https:\/\/www.cdc.gov\/heart-disease\/data-research\/facts-stats\/index.html. Accessed 14.03.2025"},{"key":"4370_CR19","doi-asserted-by":"publisher","unstructured":"Chang and Chen (2022) Potential impacts of hydralazine as a novel antioxidant on cardiovascular and renal disease-beyond vasodilation and blood pressure lowering. Antioxidants 11:2. https:\/\/doi.org\/10.3390\/antiox11112224","DOI":"10.3390\/antiox11112224"},{"key":"4370_CR20","doi-asserted-by":"crossref","unstructured":"Clinical Practice Guidelines (2020) Hypertension 75:1334\u20131357.\u00a0American Heart Association.\u00a0https:\/\/www.ahajournals.org\/doi\/epub\/10.1161\/HYPERTENSIONAHA.120.15026","DOI":"10.1161\/HYPERTENSIONAHA.120.15026"},{"key":"4370_CR21","unstructured":"CONSENSUS and SOLVD: Effect of ACE inhibition on mortality.\u00a0https:\/\/www.researchgate.net\/publication\/6602112_The_HF_epidemic_The_need_for_new_treatment_strategies"},{"key":"4370_CR22","doi-asserted-by":"publisher","unstructured":"Devarbhavi H, Bonkovsky L, Russo M, Chalasani N (2018) pp 844 to 890.e17. https:\/\/doi.org\/10.1016\/B978-0-323-37591-7.00056-2","DOI":"10.1016\/B978-0-323-37591-7.00056-2"},{"key":"4370_CR23","doi-asserted-by":"publisher","unstructured":"Donel S, Novri DA, Hamidy Y, Savira M\u00a0(2023) Effectiveness of of nifedipine, labetalol, and hydralazine as emergency antihypertension in severe preeclampsia: a randomized control trial.\u00a0F1000Research 27. https:\/\/doi.org\/10.12688\/f1000research.125944.2","DOI":"10.12688\/f1000research.125944.2"},{"key":"4370_CR24","unstructured":"Embryotox. https:\/\/www.embryotox.de\/arzneimittel\/details\/ansicht\/medikament\/dihydralazin. Accessed 06.05.2025"},{"key":"4370_CR25","unstructured":"ESC\u00a0(2024) ESC Guidelines for the management of elevated blood pressure and hypertension: Developed by the task force on the management of elevated blood pressure and hypertension of the European Society of Cardiology (ESC) and endorsed by the European Society of Endocrinology (ESE) and the European Stroke Organisation (ESO).\u00a0Eur Heart J 45:3912\u20134018. https:\/\/www.escardio.org\/Guidelines\/Clinical-Practice-Guidelines\/Elevated-Blood-Pressure-and-Hypertension"},{"key":"4370_CR26","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, Burri H, Butler J, \u010celutkien\u0117 J, Chioncel O, Cleland JGF, Coats AJS, Leiro-Crespo MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Piepoli MF, Price S, Rosano GMC, Ruschitzka F, Skibelund AK, ESC Scientific Document Group (2021) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European society of cardiology (ESC) With the special contribution of the heart failure association (HFA) of the ESC. Eur Heart J 42:3599\u20133726. https:\/\/academic.oup.com\/eurheartj\/article\/42\/36\/3599\/6358045"},{"key":"4370_CR27","doi-asserted-by":"publisher","unstructured":"Fernandes-Silva MM, Gama ACKdA, Saito GYK, Goulart BC, Mol EE, Lofrano-Alves MS (2024) Hydralazine and isosorbide dinitrate in heart failure: from evidence to clinical practice. ABC Heart Fail Cardiomyop 4:e20240019. https:\/\/doi.org\/10.36660\/abchf.20240019i","DOI":"10.36660\/abchf.20240019i"},{"key":"4370_CR28","unstructured":"Forth W, Henschler D, Rummel W (1975) Allgemeine und spezielle Pharmakologie und Toxikologie, 1st edn. Wissenschaftsverlag Bibliographisches Institut"},{"key":"4370_CR29","unstructured":"Forth W, Henschler D, Rummel W (1977) Allgemeine und spezielle Pharmakologie und Toxikologie, 2nd edn. Wissenschaftsverlag Bibliographisches Institut"},{"key":"4370_CR30","unstructured":"Forth W, Henschler D, Rummel W (1980) Allgemeine und spezielle Pharmakologie und Toxikologie, 3rd edn. Wissenschaftsverlag Bibliographisches Institut"},{"key":"4370_CR31","unstructured":"Forth W, Henschler D, Rummel W (1983) Allgemeine und spezielle Pharmakologie und Toxikologie, 4th edn. Wissenschaftsverlag Bibliographisches Institut"},{"key":"4370_CR32","unstructured":"Forth W, Henschler D, Rummel W (1987) Allgemeine und spezielle Pharmakologie und Toxikologie, 5th edn. Wissenschaftsverlag Mannheim\/Wien\/Z\u00fcrich"},{"key":"4370_CR33","unstructured":"Forth W, Henschler D, Rummel W, Starke K (1992) Allgemeine und spezielle Pharmakologie und Toxikologie, 6th edn. Wissenschaftsverlag Mannheim\/Leipzig\/Wien\/Z\u00fcrich"},{"key":"4370_CR34","unstructured":"Forth W, Henschler D, Rummel W, Starke K (1996) Allgemeine und spezielle Pharmakologie und Toxikologie, 7th edn. Spektrum Akademischer Verlag"},{"key":"4370_CR35","unstructured":"Forth W, Henschler D, Rummel W, F\u00f6rstermann U, Starke K (2001) Allgemeine und spezielle Pharmakologie und Toxikologie, 8th edn. Spektrum Urban & Fischer"},{"key":"4370_CR36","doi-asserted-by":"publisher","unstructured":"Franciosa JA, Taylor A L, Cohn JN, Yancy CW, Ziesche S, Olukotun A, Ofili E, Ferdinand K, Loscalzo J, Worcel M (2002) African-American heart failure trial (A-HeFT): rationale design and methodology. J Card Fail 8:128\u2013135. https:\/\/doi.org\/10.1054\/jcaf.2002.124730","DOI":"10.1054\/jcaf.2002.124730"},{"key":"4370_CR37","unstructured":"Gen-ethisches Netzwerk e.V. https:\/\/www.gen-ethisches-netzwerk.de\/bidil-ethnische-medizin"},{"key":"4370_CR38","unstructured":"Gilman A, Rall TW, Nies AS, Taylor P (1990) The pharmacological basis of therapeutics, 8th edn. McGraw-Hill"},{"key":"4370_CR39","doi-asserted-by":"crossref","unstructured":"Goodman L, Gilman A (1941) The pharmacological basis of therapeutics, 1st edn. Mac Millan Publishing Company","DOI":"10.1213\/00000539-194101000-00064"},{"key":"4370_CR40","unstructured":"Goodman L, Gilman A (1955) The pharmacological basis of therapeutics, 2nd edn. MacMillan Publishing Company"},{"key":"4370_CR41","unstructured":"Goodman L, Gilman A (1965) The pharmacological basis of therapeutics, 3rd edn. MacMillan Publishing Company"},{"key":"4370_CR42","unstructured":"Goodman L, Gilman A (1970) The pharmacological basis of therapeutics, 4th edn. MacMillan Publishing Company"},{"key":"4370_CR43","unstructured":"Goodman L, Gilman A (1975) The pharmacological basis of therapeutics, 5th edn. MacMillan Publishing Company"},{"key":"4370_CR44","unstructured":"Goodman L, Gilman A (1980) The pharmacological basis of therapeutics, 6th edn. MacMillan Publishing Company"},{"key":"4370_CR45","unstructured":"Goodman L, Gilman A, Rall TW, Murad F (1985) The pharmacological basis of therapeutics, 7th edn. MacMillan Publishing Company"},{"key":"4370_CR46","unstructured":"Hardman J, Limbird LE, Molinoff PB, Ruddon RW (1996) The pharmacological basis of therapeutics, 9th edn. McGraw-Hill"},{"key":"4370_CR47","unstructured":"Hardman JG, Limbird LE, Gilman A (2001) The pharmacological basis of therapeutics, 10th edn. McGraw-Hill"},{"key":"4370_CR48","unstructured":"Hochdruckliga. https:\/\/www.hochdruckliga.de\/pressemitteilung\/die-volkskrankheit-hypertonie-geht-alle-an. Accessed 06.05.2025"},{"key":"4370_CR49","unstructured":"Hydralazine Hydrochloride- hydralazine hydrochloride tablet.\u00a0Mylan Institutional Inc. https:\/\/dailymed.nlm.nih.gov\/dailymed\/lookup.cfm?setid=493a8b7e-5bb1-4db2-91a7-77ed87864131"},{"key":"4370_CR50","doi-asserted-by":"publisher","unstructured":"Iyer P, Dirweesh A, Zijoo R (2017) Hydralazine induced lupus syndrome presenting with recurrent pericardial effusion and a negative antinuclear antibody. Hindawi Publishing Corporation, pp 1\u20133. https:\/\/doi.org\/10.1155\/2017\/5245904","DOI":"10.1155\/2017\/5245904"},{"key":"4370_CR51","unstructured":"Karow T, Lang R (1993) Allgemeine und Spezielle Pharmakologie und Toxikologie, 1st edn. Thomas Karow Verlag"},{"key":"4370_CR52","unstructured":"Karow T, Lang R (1994) Allgemeine und Spezielle Pharmakologie und Toxikologie, 2nd edn. Thomas Karow Verlag"},{"key":"4370_CR53","unstructured":"Karow T, Lang R (1995) Allgemeine und Spezielle Pharmakologie und Toxikologie, 3rd edn. Thomas Karow Verlag"},{"key":"4370_CR54","unstructured":"Karow T, Lang R (1996) Allgemeine und Spezielle Pharmakologie und Toxikologie, 4th edn. Thomas Karow Verlag"},{"key":"4370_CR55","unstructured":"Karow T, Lang R (1997) Allgemeine und Spezielle Pharmakologie und Toxikologie, 5th edn. Thomas Karow Verlag"},{"key":"4370_CR56","unstructured":"Karow T, Lang R (1998) Allgemeine und Spezielle Pharmakologie und Toxikologie, 6th edn. Thomas Karow Verlag"},{"key":"4370_CR57","unstructured":"Karow T, Lang R (1999) Allgemeine und Spezielle Pharmakologie und Toxikologie, 7th edn. Thomas Karow Verlag"},{"key":"4370_CR58","unstructured":"Karow T, Lang R (2001) Allgemeine und Spezielle Pharmakologie und Toxikologie, 9th edn. Thomas Karow Verlag"},{"key":"4370_CR59","unstructured":"Karow T, Lang R (2002) Allgemeine und Spezielle Pharmakologie und Toxikologie, 10th edn. Thomas Karow Verlag"},{"key":"4370_CR60","unstructured":"Karow T, Lang-Roth R (2003) Allgemeine und Spezielle Pharmakologie und Toxikologie, 11th edn. Thomas Karow Verlag"},{"key":"4370_CR61","unstructured":"Karow T, Lang-Roth R (2004) Allgemeine und Spezielle Pharmakologie und Toxikologie, 12th edn. Thomas Karow Verlag"},{"key":"4370_CR62","unstructured":"Karow T, Lang-Roth R (2005) Allgemeine und Spezielle Pharmakologie und Toxikologie, 13th edn. Thomas Karow Verlag"},{"key":"4370_CR63","unstructured":"Karow T, Lang-Roth R (2006) Allgemeine und Spezielle Pharmakologie und Toxikologie, 14th edn. Thomas Karow Verlag"},{"key":"4370_CR64","unstructured":"Karow T, Lang-Roth R (2007) Allgemeine und Spezielle Pharmakologie und Toxikologie, 15th edn. Thomas Karow Verlag"},{"key":"4370_CR65","unstructured":"Karow T, Lang-Roth R (2008) Allgemeine und Spezielle Pharmakologie und Toxikologie, 16th edn. Thomas Karow Verlag"},{"key":"4370_CR66","unstructured":"Karow T, Lang-Roth R (2009) Allgemeine und Spezielle Pharmakologie und Toxikologie, 17th edn. Thomas Karow Verlag"},{"key":"4370_CR67","unstructured":"Karow T, Lang-Roth R (2010) Allgemeine und Spezielle Pharmakologie und Toxikologie, 18th edn. Thomas Karow Verlag"},{"key":"4370_CR68","unstructured":"Karow T, Lang-Roth R (2011) Allgemeine und Spezielle Pharmakologie und Toxikologie, 19th edn. Thomas Karow Verlag"},{"key":"4370_CR69","unstructured":"Karow T, Lang-Roth R (2012) Allgemeine und Spezielle Pharmakologie und Toxikologie, 20th edn. Thomas Karow Verlag"},{"key":"4370_CR70","unstructured":"Karow T, Lang-Roth R (2013) Allgemeine und Spezielle Pharmakologie und Toxikologie, 22nd edn. Thomas Karow Verlag"},{"key":"4370_CR71","unstructured":"Karow T, Lang-Roth R (2014) Allgemeine und Spezielle Pharmakologie und Toxikologie, 23rd edn. Thomas Karow Verlag"},{"key":"4370_CR72","unstructured":"Karow T, Lang-Roth R (2015) Allgemeine und Spezielle Pharmakologie und Toxikologie, 24th edn. Thomas Karow Verlag"},{"key":"4370_CR73","unstructured":"Karow T, Lang-Roth R (2016) Allgemeine und Spezielle Pharmakologie und Toxikologie, 25th edn. Thomas Karow Verlag"},{"key":"4370_CR74","unstructured":"Karow T, Lang-Roth R (2017) Allgemeine und Spezielle Pharmakologie und Toxikologie, 26th edn. Thomas Karow Verlag"},{"key":"4370_CR75","unstructured":"Karow T, Lang-Roth R (2018) Allgemeine und Spezielle Pharmakologie und Toxikologie, 27th edn. Thomas Karow Verlag"},{"key":"4370_CR76","unstructured":"Karow T, Lang-Roth R (2019) Allgemeine und Spezielle Pharmakologie und Toxikologie, 28th edn. Thomas Karow Verlag"},{"key":"4370_CR77","unstructured":"Karow T, Lang-Roth R (2020) Allgemeine und Spezielle Pharmakologie und Toxikologie, 29th edn. Thomas Karow Verlag"},{"key":"4370_CR78","unstructured":"Karow T, Lang-Roth R (2021) Allgemeine und Spezielle Pharmakologie und Toxikologie, 30th edn. Thomas Karow Verlag"},{"key":"4370_CR79","unstructured":"Karow T, Lang-Roth R (2022) Allgemeine und Spezielle Pharmakologie und Toxikologie, 31st edn. Thomas Karow Verlag"},{"key":"4370_CR80","unstructured":"Karow T, Lang-Roth R (2023) Allgemeine und Spezielle Pharmakologie und Toxikologie, 32nd edn. Thomas Karow Verlag"},{"key":"4370_CR81","unstructured":"Karow T, Lang-Roth R (2024) Allgemeine und Spezielle Pharmakologie und Toxikologie, 33rd edn. Thomas Karow Verlag"},{"key":"4370_CR82","doi-asserted-by":"crossref","unstructured":"Katz U, Goddard GZ (2010) Drug-induced lupus: an update. ScienceDirect,\u00a0pp 46\u201350","DOI":"10.1016\/j.autrev.2010.07.005"},{"key":"4370_CR83","unstructured":"Kuschinsky G, L\u00fcllmann H (1964) Kurzes Lehrbuch der Pharmakologie, 1st edn. Georg Thieme Verlag"},{"key":"4370_CR84","doi-asserted-by":"crossref","unstructured":"Kuschinsky G, L\u00fcllmann H (1966) Kurzes Lehrbuch der Pharmakologie, 2nd edn. Georg Thieme Verlag","DOI":"10.1097\/00000441-196610000-00024"},{"key":"4370_CR85","unstructured":"Kuschinsky G, L\u00fcllmann H (1967) Kurzes Lehrbuch der Pharmakologie, 3rd edn. Georg Thieme Verlag"},{"key":"4370_CR86","unstructured":"Kuschinsky G, L\u00fcllmann H (1970) Kurzes Lehrbuch der Pharmakologie, 4th edn. Georg Thieme Verlag"},{"key":"4370_CR87","unstructured":"Kuschinsky G, L\u00fcllmann H (1972) Kurzes Lehrbuch der Pharmakologie, 5th edn. Georg Thieme Verlag"},{"key":"4370_CR88","unstructured":"Kuschinsky G, L\u00fcllmann H (1974) Kurzes Lehrbuch der Pharmakologie, 6th edn. Georg Thieme Verlag"},{"key":"4370_CR89","unstructured":"Kuschinsky G, L\u00fcllmann H (1976) Kurzes Lehrbuch der Pharmakologie, 7th edn. Georg Thieme Verlag"},{"key":"4370_CR90","unstructured":"Kuschinsky G, L\u00fcllmann H (1978) Kurzes Lehrbuch der Pharmakologie, 8th edn. Georg Thieme Verlag"},{"key":"4370_CR91","unstructured":"Kuschinsky G, L\u00fcllmann H (1981) Kurzes Lehrbuch der Pharmakologie, 9th edn. Georg Thieme Verlag"},{"key":"4370_CR92","unstructured":"Kuschinsky G, L\u00fcllmann H (1984) Kurzes Lehrbuch der Pharmakologie, 10th edn. Georg Thieme Verlag"},{"key":"4370_CR93","unstructured":"Kuschinsky G, L\u00fcllmann H (1987) Kurzes Lehrbuch der Pharmakologie, 11th edn. Georg Thieme Verlag"},{"key":"4370_CR94","unstructured":"Kuschinsky G, L\u00fcllmann H (1989) Kurzes Lehrbuch der Pharmakologie, 12th edn. Georg Thieme Verlag"},{"key":"4370_CR95","unstructured":"Kuschinsky G, L\u00fcllmann H (1993) Kurzes Lehrbuch der Pharmakologie, 13th edn. Thieme Verlag"},{"key":"4370_CR96","unstructured":"Leitlinienprogramm Deutsche Gesellschaft f\u00fcr Gyn\u00e4kologie und Geburtshilfe (DGGG) (2018) \u00d6sterreichische Gesellschaft f\u00fcr Gyn\u00e4kologie und Geburtshilfe (OEGGG), Schweizerische Gesellschaft f\u00fcr Gyn\u00e4kologie und Geburtshilfe (SGGG), Hypertensive Schwangerschaftserkrankungen: Diagnostik und Therapie. https:\/\/register.awmf.org\/assets\/guidelines\/015-018l_S2k_Diagnostik_Therapie_hypertensiver_Schwangerschaftserkrankungen_2019-07.pdf"},{"key":"4370_CR97","doi-asserted-by":"crossref","unstructured":"Ludwig W-D, M\u00fchlbauer B, Seifert R (2021) Arzneiverordnungsreport 2021. Springer","DOI":"10.1007\/978-3-662-63825-5"},{"key":"4370_CR98","doi-asserted-by":"crossref","unstructured":"Ludwig W-D, M\u00fchlbauer B, Seifert R (2022) Arzneiverordnungsreport 2022. Springer","DOI":"10.1007\/978-3-662-66303-5"},{"key":"4370_CR99","doi-asserted-by":"crossref","unstructured":"Ludwig W-D, M\u00fchlbauer B, Seifert R (2023) Arzneiverordnungsreport 2023. Springer","DOI":"10.1007\/978-3-662-68371-2"},{"key":"4370_CR100","unstructured":"L\u00fcllmann H, Mohr K (1999) Pharmakologie und Toxikologie, 14th edn. Thieme Verlag, L\u00fcllmann, founded by: Kuschinky Gustav; Heinz L\u00fcllmann"},{"key":"4370_CR101","unstructured":"L\u00fcllmann H, Mohr K, Wehling M (2003) Pharmakologie und Toxikologie, 15th edn. Thieme Verlag, L\u00fcllmann, founded by: Kuschinky Gustav; Heinz L\u00fcllmann"},{"key":"4370_CR102","doi-asserted-by":"crossref","unstructured":"L\u00fcllmann H, Mohr K, Hein L (2006) Pharmakologie und Toxikologie, 16th edn. Thieme Verlag, L\u00fcllmann, founded by: Kuschinky Gustav; Heinz L\u00fcllmann","DOI":"10.1055\/b-0034-43566"},{"key":"4370_CR103","doi-asserted-by":"crossref","unstructured":"L\u00fcllmann H, Mohr K, Hein L (2010) Pharmakologie und Toxikologie, 17th edn. Georg Thieme Verlag, L\u00fcllmann, founded by: Kuschinky Gustav; Heinz L\u00fcllmann","DOI":"10.1055\/b-002-44917"},{"key":"4370_CR104","doi-asserted-by":"crossref","unstructured":"L\u00fcllmann H, Mohr K, Wehling M, Hein L (2016) Pharmakologie und Toxikologie, 18th edn. Thieme Verlag, L\u00fcllmann, founded by: Kuschinky Gustav; Heinz L\u00fcllmann","DOI":"10.1055\/b-004-129674"},{"key":"4370_CR105","doi-asserted-by":"publisher","unstructured":"Misera N, Seifert R (2024) Presentation of the obsolete drug reserpine in three German-language pharmacology textbooks. Naunyn-Schmiedeberg's Arch Pharmacol 397(6):4381\u20134401. https:\/\/doi.org\/10.1007\/s00210-023-02877-9","DOI":"10.1007\/s00210-023-02877-9"},{"key":"4370_CR106","unstructured":"Morand P, Lavigne G, Masson D, Latour F, Anson D (1979) Treatment of severe chronic cardiac insufficiency with dihydralazine. Short-and median-term results. Arch Mal C\u0153ur Vaiss 72:268\u2013275. https:\/\/pubmed.ncbi.nlm.nih.gov\/114137\/"},{"key":"4370_CR107","unstructured":"NIH. Hydralazine. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK470296\/. Accessed 22.04.2025"},{"key":"4370_CR108","unstructured":"NVL Hypertension (2023) https:\/\/register.awmf.org\/assets\/guidelines\/nvl-009k_S3_Hypertonie_2023-06.pdf"},{"key":"4370_CR109","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/0735-1097(88)92615-0","volume":"12","author":"M Packer","year":"1988","unstructured":"Packer M (1988) Vasodilator and inotropic drugs for the treatment of chronic heart failure: distinguishing hype from hope. J Am Coll Cardiol 12:1299\u20131317. https:\/\/doi.org\/10.1016\/0735-1097(88)92615-0","journal-title":"J Am Coll Cardiol"},{"key":"4370_CR110","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/0002-9343(73)90084-3","volume":"54","author":"HM Perry","year":"1973","unstructured":"Perry HM (1973) Late Toxicity to Hydralazine Resembling Systemic Lupus erythematosus or Rheumatoid Arthritis. Am J Med 54:58\u201372. https:\/\/doi.org\/10.1016\/0002-9343(73)90084-3","journal-title":"Am J Med"},{"key":"4370_CR111","unstructured":"Pharmazeutische Zeitung (2023) https:\/\/www.pharmazeutische-zeitung.de\/medikationsanalyse-ohne-arztruecksprache-139139\/seite\/2\/?cHash=89ba7cbe365af683847527b32f9b0482"},{"key":"4370_CR112","unstructured":"PubChem. Hydralazine. https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/3637. Accessed 23.04.2025"},{"key":"4370_CR113","doi-asserted-by":"crossref","unstructured":"Reifert N, Bussmann W.-D. (1986) Wirkungsabschw\u00e4chung bei der Langzeittherapie der chronischen Herzinsuffizienz mit Dihydralazin, pp. 68\u201375. https:\/\/link.springer.com\/chapter\/10.1007\/978-3-642-71486-3_10","DOI":"10.1007\/978-3-642-71486-3_10"},{"key":"4370_CR114","unstructured":"Rote Liste (1959) Bundesverband der Pharmazeutischen Industrie e.V."},{"key":"4370_CR115","unstructured":"Rote Liste (1967) Bundesverband der Pharmazeutischen Industrie e.V."},{"key":"4370_CR116","unstructured":"Rote Liste (1975) Bundesverband der Pharmazeutischen Industrie e.V."},{"key":"4370_CR117","unstructured":"Rote Liste (1985) Bundesverband der Pharmazeutischen Industrie e.V."},{"key":"4370_CR118","unstructured":"Rote Liste (1994) Bundesverband der Pharmazeutischen Industrie e.V."},{"key":"4370_CR119","unstructured":"Rote Liste (2005) Rote Liste Service GmBH"},{"key":"4370_CR120","unstructured":"Rote Liste (2018) Rote Liste Service GmBH"},{"key":"4370_CR121","unstructured":"Rote Liste (2024) Rote Liste Service GmBH"},{"key":"4370_CR122","doi-asserted-by":"crossref","unstructured":"Schwabe U, Paffrath D (1999) Arzneiverordnungsreport 1998. Springer","DOI":"10.1007\/978-3-642-58436-7"},{"key":"4370_CR123","doi-asserted-by":"crossref","unstructured":"Schwabe U, Paffrath D (2000) Arzneiverordnungsreport 1999. Springer","DOI":"10.1007\/978-3-642-57215-9"},{"key":"4370_CR124","doi-asserted-by":"crossref","unstructured":"Schwabe U, Paffrath D (2001a) Arzneiverordnungsreport 2000. Springer","DOI":"10.1007\/978-3-642-56832-9"},{"key":"4370_CR125","doi-asserted-by":"crossref","unstructured":"Schwabe U, Paffrath D (2001b) Arzneiverordnungsreport 2001. Springer","DOI":"10.1007\/978-3-642-56434-5"},{"key":"4370_CR126","doi-asserted-by":"crossref","unstructured":"Schwabe U, Paffrath D (2003) Arzneiverordnungsreport 2002. Springer","DOI":"10.1007\/978-3-662-11173-4"},{"key":"4370_CR127","doi-asserted-by":"crossref","unstructured":"Schwabe U, Paffrath D (2004) Arzneiverordnungsreport 2003. Springer","DOI":"10.1007\/978-3-642-18512-0"},{"key":"4370_CR128","doi-asserted-by":"crossref","unstructured":"Schwabe U, Paffrath D (2005) Arzneiverordnungsreport 2004. Springer","DOI":"10.1007\/978-3-642-18513-7"},{"key":"4370_CR129","doi-asserted-by":"crossref","unstructured":"Schwabe U, Paffrath D (2006) Arzneiverordnungsreport 2005. Springer","DOI":"10.1007\/3-540-30505-X"},{"key":"4370_CR130","doi-asserted-by":"crossref","unstructured":"Schwabe U, Paffrath D (2007) Arzneiverordnungsreport 2006. Springer","DOI":"10.1007\/978-3-540-34370-7"},{"key":"4370_CR131","doi-asserted-by":"crossref","unstructured":"Schwabe U, Paffrath D (2008a) Arzneiverordnungsreport 2007. Springer","DOI":"10.1007\/978-3-540-72548-0"},{"key":"4370_CR132","doi-asserted-by":"crossref","unstructured":"Schwabe U, Paffrath D (2008b) Arzneiverordnungsreport 2008. Springer","DOI":"10.1007\/978-3-540-69219-5"},{"key":"4370_CR133","doi-asserted-by":"crossref","unstructured":"Schwabe U, Paffrath D (2009) Arzneiverordnungsreport 2009. Springer","DOI":"10.1007\/978-3-642-01080-4"},{"key":"4370_CR134","doi-asserted-by":"crossref","unstructured":"Schwabe U, Paffrath D (2010) Arzneiverordnungsreport 2010. Springer","DOI":"10.1007\/978-3-642-13380-0"},{"key":"4370_CR135","doi-asserted-by":"crossref","unstructured":"Schwabe U, Paffrath D (2011) Arzneiverordnungsreport 2011. Springer","DOI":"10.1007\/978-3-642-21992-4"},{"key":"4370_CR136","doi-asserted-by":"crossref","unstructured":"Schwabe U, Paffrath D (2012) Arzneiverordnungsreport 2012. Springer","DOI":"10.1007\/978-3-642-29242-2"},{"key":"4370_CR137","doi-asserted-by":"crossref","unstructured":"Schwabe U, Paffrath D (2013) Arzneiverordnungsreport 2013. Springer","DOI":"10.1007\/978-3-642-37124-0"},{"key":"4370_CR138","doi-asserted-by":"crossref","unstructured":"Schwabe U, Paffrath D (2014) Arzneiverordnungsreport 2014. Springer","DOI":"10.1007\/978-3-662-43487-1"},{"key":"4370_CR139","doi-asserted-by":"crossref","unstructured":"Schwabe U, Paffrath D (2015) Arzneiverordnungsreport 2015. Springer","DOI":"10.1007\/978-3-662-47186-9"},{"key":"4370_CR140","doi-asserted-by":"crossref","unstructured":"Schwabe U, Paffrath D (2016) Arzneiverordnungsreport 2016. Springer","DOI":"10.1007\/978-3-662-50351-5"},{"key":"4370_CR141","doi-asserted-by":"crossref","unstructured":"Schwabe U, Paffrath D, Ludwig W-D, Klauber J (2017) Arzneiverordnungsreport 2017 Springer","DOI":"10.1007\/978-3-662-54630-7"},{"key":"4370_CR142","doi-asserted-by":"crossref","unstructured":"Schwabe U, Paffrath D, Ludwig W-D, Klauber J (2018) Arzneiverordnungsreport 2018 Springer","DOI":"10.1007\/978-3-662-57386-0"},{"key":"4370_CR143","doi-asserted-by":"crossref","unstructured":"Schwabe U, Paffrath D, Ludwig W-D, Klauber J (2019) Arzneiverordnungsreport 2019 Springer","DOI":"10.1007\/978-3-662-59046-1"},{"key":"4370_CR144","doi-asserted-by":"crossref","unstructured":"Schwabe U, Ludwig W-D (2020) Arzneiverordnungsreport 2020 Springer","DOI":"10.1007\/978-3-662-62168-4"},{"key":"4370_CR145","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.kint.2016.07.042","volume":"91","author":"B Tampe","year":"2017","unstructured":"Tampe B, Steinle U, Tampe D, Carstens JL, Korsten P, Zeisberg EM, M\u00fcller GA, Kalluri R, Zeisberg M (2017) Low-dose hydralazine prevents fibrosis in a murine model of acute kidney injury-to-chronic kidney disease progression. Kidney Int 91:157\u2013176. https:\/\/doi.org\/10.1016\/j.kint.2016.07.042","journal-title":"Kidney Int"},{"key":"4370_CR146","unstructured":"Technical information (2001)\u00a0https:\/\/arzneimittel-cdn.amboss.com\/Fachinformation\/138223.pdf"},{"key":"4370_CR147","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7759\/cureus.4996","volume":"11","author":"H Timlin","year":"2019","unstructured":"Timlin H, Wu M, Crespo-Bosque M, Geetha D, Ingolia A, Haque U, Towns MC, Beck TG (2019) Clinical characteristics of hydralazine-induced lupus. Cureus 11:1\u20138. https:\/\/doi.org\/10.7759\/cureus.4996","journal-title":"Cureus"},{"key":"4370_CR148","unstructured":"V-HeFT II. Wiki Journal Club.\u00a0https:\/\/www.wikijournalclub.org\/wiki\/V-HeFT_II#:~:text=,symptomatic%20HFrEF%20who%20cannot%20be. Accessed 10.05.2025"},{"key":"4370_CR149","unstructured":"Via medici. https:\/\/viamedici.thieme.de\/. Accessed 08.03.2025"},{"key":"4370_CR150","doi-asserted-by":"crossref","unstructured":"Wacker J, Werner P, Walter-Sack I, Bastert G (1998) Treatment of hypertension in patients with preeclampsia: a prospective parallel-group study comparing dihydralazine with urapidil. Nephrol Dial Transplant 13:318\u201325","DOI":"10.1093\/oxfordjournals.ndt.a027825"},{"key":"4370_CR151","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.ejogrb.2005.09.013","volume":"127","author":"JR Wacker","year":"2006","unstructured":"Wacker JR, Wagner BK, Briese V, Schauf B, Heilmann L, Bartz C (2006) Hopp H Antihypertensive therapy in patients with pre-eclampsia: A prospective randomized multicenter study comparing dihydralazine with urapidil. Eur J Obstet Gynecol Reprod Biol 127:160\u2013165. https:\/\/doi.org\/10.1016\/j.ejogrb.2005.09.013","journal-title":"Eur J Obstet Gynecol Reprod Biol"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04370-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-04370-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04370-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T22:02:29Z","timestamp":1771538549000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-04370-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,9]]},"references-count":151,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["4370"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-04370-x","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,9]]},"assertion":[{"value":"30 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the guidelines of good scientific practice of Hannover Medical School (\n                      \n                      ) and officially registered specifically as a doctoral project for Carina Mech. The Hannover Medical School follows the guidelines of the German Research Foundation (DFG).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable because publicly available information is used as data source.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"R.S. is the Editor-in-Chief of Naunyn-Schmiedebergs Arch Pharmacol and follows the editorial guidelines of editors acting as authors (\n                      \n                      ).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}